Sections
Title | Starting Page | Number of Pages |
---|
1 Table of Contents | 2 | 2 |
1.1 List of Tables | 3 | 1 |
1.2 List of Figures | 3 | 1 |
2 Executive Summary | 4 | 1 |
2.1 Low Prevalence but a High Unmet Need and a Limited Number of Marketed Options | 4 | 1 |
2.2 Moderately Sized but Innovative Pipeline | 4 | 1 |
2.3 Moderately Active Deals Landscape, Mostly Involving Currently Established Targets | 4 | 1 |
3 The Case for Innovation in the Glioblastoma Multiforme Market | 5 | 3 |
3.1 Growing Opportunities for Biologic Products | 5 | 1 |
3.2 Diversification of Molecular Targets | 6 | 1 |
3.3 Innovative First-in-Class Product Developments Remain Attractive | 6 | 1 |
3.4 Changes in Clinical and Commercial Environment to be More Favorable to Products Targeting Niche Patient Populations and Indications | 6 | 1 |
3.5 Sustained Innovation | 7 | 1 |
3.6 Report Guidance | 7 | 1 |
4 Clinical and Commercial Landscape | 8 | 16 |
4.1 Disease Overview | 8 | 1 |
4.2 Epidemiology | 8 | 1 |
4.3 Disease Symptoms | 8 | 1 |
4.4 Etiology | 9 | 1 |
4.4.1 Age, Rae and Gender | 9 | 1 |
4.4.2 Genetic Factors | 10 | 1 |
4.4.3 Environmental Factors | 10 | 1 |
4.5 Pathophysiology | 11 | 1 |
4.5.1 Tumor Initiation and Aberrant Cell Proliferation and Survival | 11 | 1 |
4.5.2 Tumor Metabolic Shift | 12 | 1 |
4.5.3 Tumor Progression, Micro-environment Alteration and Angiogenesis | 12 | 1 |
4.5.4 Cancer Stem Cells | 13 | 1 |
4.6 Diagnosis | 14 | 1 |
4.7 GBM Prognosis and Prognostic Factors | 15 | 1 |
4.8 Classification | 15 | 1 |
4.8.1 Loss of Heterozygosity of Chromosome 10 | 16 | 1 |
4.8.2 Epidermal Growth Factor Receptor Amplification | 17 | 1 |
4.8.3 Phosphatase and Tensin Homolog Mutation | 17 | 1 |
4.8.4 Loss of p53 Function | 17 | 1 |
4.8.5 p16INK4a Alteration and Loss of Normal Retinoblastoma 1 Function | 17 | 1 |
4.8.6 Isocitrate Dehydrogenase 1 or Isocitrate Dehydrogenase 2 Mutation | 18 | 1 |
4.9 Glioblastoma Multiforme Treatment | 18 | 1 |
4.10 Surgery and Radiation Therapy | 18 | 1 |
4.11 Overview of Marketed Products for Glioblastoma Multiforme | 19 | 1 |
4.11.1 Chemotherapy | 20 | 1 |
4.11.2 Targeted Therapies | 21 | 1 |
4.12 Treatment Algorithm | 21 | 2 |
4.13 Current Unmet Need in the GBM Market | 23 | 1 |
5 Assessment of Pipeline Product Innovation | 24 | 9 |
5.1 Glioblastoma Pipeline by Phase, Molecule Type and Molecular Target | 24 | 4 |
5.2 First-in-Class Pipeline Programs | 28 | 5 |
6 Signaling Network, Disease Causation and Innovation Alignment | 33 | 3 |
6.1 The Complexity of Signaling Networks in Oncology | 33 | 1 |
6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration | 34 | 1 |
6.3 First-in-Class Target Matrix Assessment | 34 | 2 |
7 First-in-Class Target Evaluation | 36 | 12 |
7.1 Pipeline Programs Targeting AKT 1 and 2 | 36 | 1 |
7.2 Pipeline Programs Targeting CDK1/2 | 37 | 1 |
7.3 Pipeline Programs Targeting PIK3CB and PIK3CG | 38 | 1 |
7.4 Pipeline Programs which Target NTRK1 | 39 | 2 |
7.5 Pipeline Programs Targeting XIAP | 41 | 1 |
7.6 Pipeline Programs Targeting Myc | 42 | 1 |
7.7 Pipeline Programs Targeting PRKCA | 43 | 1 |
7.8 Pipeline Programs which Target CASP8 and CASP9 | 44 | 1 |
7.9 Pipeline Programs which Target NR4A1 | 45 | 1 |
| 45 | 2 |
7.11 Conclusion | 47 | 1 |
8 Deals and Strategic Consolidations | 48 | 11 |
8.1 Industry-Wide First-in-Class Deals | 48 | 1 |
8.2 Glioblastoma Multiforme Deals Landscape | 49 | 1 |
8.3 Licensing Deals | 50 | 2 |
8.3.1 Molecule Type | 52 | 1 |
8.3.2 Molecular Target | 52 | 1 |
8.4 Co-development Deals | 53 | 2 |
8.4.1 Molecule Type | 55 | 1 |
8.4.2 Molecular Target | 55 | 2 |
8.5 List of Pipeline Products without Prior Licensing or Co-Development Deal Involvement | 57 | 2 |
9 Appendix | 59 | 15 |
9.1 Abbreviations | 59 | 1 |
9.2 References | 60 | 11 |
9.3 Research Methodology | 71 | 1 |
9.4 Secondary Research | 71 | 2 |
9.4.1 Market Analysis | 71 | 1 |
9.4.2 Pipeline Analysis | 71 | 1 |
9.4.2.1 Overall Pipeline | 71 | 1 |
9.4.2.2 First-in-Class Analysis | 72 | 1 |
9.4.3 First-in-Class Matrix Assessment | 72 | 1 |
9.4.4 First-in-Class Target Profiles | 72 | 1 |
9.4.5 Licensing and Co-Development Deals | 72 | 1 |
9.5 Contact Us | 73 | 1 |
9.6 Disclaimer | 73 | 1 |